Development of a first-in-class inhibitor of FIH for cancer immunotherapy

We plan to carry out a valorisation project for a series of novel small molecule inhibitors of Factor Inhibiting HIF (FIH) that we have developed for the treatment of lung cancer, as a next-generation therapeutic approach in the field of immuno-oncology.The valorisation plan will include: clarification of IP rights and strategy, establishing contacts with potential investors and pharma partners, and verification of the potential of start-up creation. Moreover, valorisation activities will include progression of hits against FIH into a lead optimisation campaign with the aim of designating a candidate drug.